The practice of “surprising” patients with unexpected, exorbitant bills needs to stop and insurance companies need to become responsible for reasonable out of network medical expenses
As early as 2013, we have known that a lower baseline prostate-specific antigen (PSA) is associated with a higher overall survival benefit from Provenge (sipuleucel-T)
Prostate cancer treatments have been targeting the androgen receptor for over 80 years, and the vast majority of our new treatments also continue to target the androgen receptor. Prostate cancer treatments have failed to include new classes of treatments when compared to other cancers.
There was a small clinical trial, by Mark Ratain, M.D., of the University of Chicago, that suggests that it is possible to take a lower dose of Zytiga (abiraterone) along with a low-fat breakfast and achieve a response similar to the one we would expect to see with a full dose on an empty stomach.
How best to treat oligometastatic prostate cancer is still not clear, but there are several on-going studies designed to determine what should be best practices. Although not yet completed, these studies do indicate that metastasis-directed therapy (MDT) and local therapy targeted to the primary tumor (in the prostate gland) may be of benefit in the setting of oligometastatic disease.
Dr. Howard Soule of the Prostate Cancer Foundation has long discussed the Three Ds of successful cancer treatment. Using Dr. Soule’s paradigm really allows us to understand the cancer treatment process and more importantly where we are failing in treating patients.
Debulking, or lowering the tumor load, might provide over all survival benefits for men diagnosed with prostate cancer.
African American men face many different health disparities with most of the disparities being weighed against them. There is one notable exception, African American (AA) men have a huge, significant overall survival benefit when given Sipuleucel-T (Provenge) equal to 9.5 months over their Caucasian counterparts!
The National Comprehensive Cancer Network (NCCN) serves as a generally accepted cookbook or road map for doctors as they put together treatment plans for their patients. The NCCN relies on evidence-based findings as well as FDA approvals. Their guidelines create the standard of care for the treatment of serious disease, including cancer.
As it just did, the NCCN periodically releases updates to their guidelines for prostate cancer treatment.
Why is Evaluating Quality of Life (QoL) in Clinical Trials is Important
The project’s goal is to have thousands and thousands of men with metastatic prostate cancer share their medical records, their DNA and their tumor tissue so that we can understand the genomics of this disease, learn how it progresses and how resistance to treatments develop.
Basic statistics about advanced prostate cancer.
A recent phase II clinical trial described at the 2019 ASCO GU meeting using a combination of two immunotherapy drugs in metastatic prostate cancer has shown some positive activity.
At the recent ASCO GU conference, we learned the results from the ARAMUS phase III trial which evaluated Darolutamide, an androgen receptor (AR) antagonist (a drug that prevents androgens from affecting prostate and prostate cancer cells). The trial studied the efficacy and safety of darolutamide in men with nmCRPC men.
African American Men experience a survival advantage over Caucasian Men when they take either Zytiga or Xtandi.
Co-pay assistance is now available for advanced Prostate Cancer drugs.
Studies consistently show that most clinical trial participants want to know what the research communities learned from their participation, yet most never hear from the sponsor or research site staff at all after a clinical trial has concluded. A growing number of pharmaceutical, biotechnology, and medical device companies have recognized this situation and are closing the loop with their study volunteers by providing clinical trial results summaries, also known as lay language or plain language summaries.
You can participate on an editorial board that produces documents provided to clinical trial participants describing the trial and its results.
A preplanned early analysis of the Phase III TITAN trial shows that Erleada (apalutamide) has met the both of the trial’s primary endpoints in the treatment of men with metastatic castration-sensitive prostate cancer (CSPC).
The Food and Drug Administration (FDA) has approved a new Phase 1 clinical trial to evaluate ARV-110 for men with metastatic castration-resistant prostate cancer (mCRPC).
Reach out to the PAN Foundation to see if you qualify for economic support for your prostate cancer drugs.